BioCentury | Sep 14, 2018
Emerging Company Profile

Laekna’s jumping off place

Chinese biotech Laekna Therapeutics Shanghai Co. Ltd. is jump-starting its pipeline with a trio of clinical cancer compounds from Novartis AG. The safety of the lead candidate and its potential to synergize with the other...
BC Week In Review | Aug 3, 2018
Company News

Laekna gets rights to Novartis cancer candidates

Laekna Therapeutics Shanghai Co. Ltd. (Shanghai, China) acquired exclusive, worldwide rights to develop and commercialize two clinical stage cancer compounds from Novartis AG (NYSE:NVS; SIX:NOVN). The pharma will take an equity stake in Laekna, which...
BC Extra | Aug 1, 2018
Company News

Laekna gets rights to Novartis cancer candidates

Laekna Therapeutics Shanghai Co. Ltd. (Shanghai, China) acquired exclusive, worldwide rights to develop and commercialize two clinical stage cancer compounds from Novartis AG (NYSE:NVS; SIX:NOVN). The pharma will take an equity stake in Laekna, which...
BC Week In Review | Jun 13, 2016
Clinical News

Afuresertib: Phase I/II data

Data from 29 patients with recurrent ovarian cancer in the Phase I portion of an open-label, international Phase I/II trial showed that once-daily oral afuresertib plus paclitaxel and carboplatin led to dose-limiting toxicities (DLTs) of...
BC Week In Review | Apr 28, 2014
Company News

GlaxoSmithKline, Novartis deal

Novartis and GlaxoSmithKline announced multi-billion dollar deals that will see the pharmas sell assets to one another. Novartis will bolster its portfolio of marketed cancer drugs and GSK will bulk up its vaccine business. The...
BioCentury | Apr 28, 2014
Strategy

Bigger is better

Novartis AG is showing every sign of continuing to think big. Ridding itself of low-performing businesses while doubling down on cancer will help the pharma increase its operating income in the short term and plug...
BC Extra | Apr 23, 2014
Top Story

Novartis, GSK swapping assets

Novartis AG (NYSE:NVS; SIX:NOVN) and GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) announced multi-billion dollar deals that will see the pharmas sell assets to one another. Novartis will bolster its portfolio of marketed cancer drugs and GSK will...
Items per page:
1 - 7 of 7